Intermediate-size trials for the evaluation of HIV vaccine candidates: a workshop summary.
about
Effect of race/ethnicity on participation in HIV vaccine trials and comparison to other trials of biomedical preventionHIV vaccine preparedness studies in the organization for economic co-operation and development (OECD) countries.Sensitivity analysis for the assessment of causal vaccine effects on viral load in HIV vaccine trials.Evaluation of performance of the Gen-Probe human immunodeficiency virus type 1 viral load assay using primary subtype A, C, and D isolates from Kenya.Some design issues in phase 2B vs phase 3 prevention trials for testing efficacy of products or conceptsIncreasing the Efficiency of Prevention Trials by Incorporating Baseline CovariatesFishermen as a Suitable Population for HIV Intervention TrialsStatistical interpretation of the RV144 HIV vaccine efficacy trial in Thailand: a case study for statistical issues in efficacy trials.Randomization-Based Inference within Principal Strata.Willingness to participate in future HIV prevention studies among gay and bisexual men in Scotland, UK: a challenge for intervention trials.HIV Vaccine Trials Network: activities and achievements of the first decade and beyond.Endpoints and regulatory issues in HIV vaccine clinical trials: lessons from a workshop.In pursuit of an HIV vaccine: designing efficacy trials in the context of partially effective nonvaccine prevention modalitiesNew clinical trial designs for HIV vaccine evaluation.Use of calibrated viral load standards for group M subtypes of human immunodeficiency virus type 1 to assess the performance of viral RNA quantitation tests.Basis and Statistical Design of the Passive HIV-1 Antibody Mediated Prevention (AMP) Test-of-Concept Efficacy Trials.Bayesian estimation of vaccine efficacy.Bias reduction for risk ratio and vaccine effect estimators.
P2860
Q30206105-18DB09D9-044B-40EA-8F9D-455B7D82F168Q30229401-FA3B9A4E-36B8-4FF3-B75E-DA1756981756Q30336405-3749F871-6F17-4944-908C-16B14B80E885Q33968241-B1ABA794-0C99-4323-A7C2-0C519B57C62AQ34090592-B5488E9D-BD50-48FD-887D-10D199C5D5DFQ34383812-47826DB8-EE94-4748-94B3-6FA52CFB3D47Q34730059-F8E56291-5070-410D-AB1C-3D1A691CD138Q34743329-ECC275A5-DC9C-4AD4-937E-E434155C6586Q35285899-FB5FC99A-AE97-4FC0-94F8-F7D65FE49144Q36106497-0883F545-699C-488D-82D6-957B38115466Q36464748-5372DC00-3C2B-4F58-A1DB-5E0A18223CD7Q37194359-E2EE2AA0-89E5-46A3-9468-79F669F8DA29Q37258303-3726A1BC-DE7A-4A05-8547-C40B0112F109Q37412300-FD4B7777-F984-4DD7-9870-C662546D6008Q39456289-0BFC73D4-7583-40C5-B913-358FB56B0998Q46296261-5D0072CE-F6DF-4667-9103-F2A0BA3DD6B1Q51960395-09340F83-D74B-4F14-956E-A898C828D131Q52061490-5B0BD6F3-070D-4AA7-83BC-7FECA4311EAF
P2860
Intermediate-size trials for the evaluation of HIV vaccine candidates: a workshop summary.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年学术文章
@wuu
1997年学术文章
@zh
1997年学术文章
@zh-cn
1997年学术文章
@zh-hans
1997年学术文章
@zh-my
1997年学术文章
@zh-sg
1997年學術文章
@yue
1997年學術文章
@zh-hant
name
Intermediate-size trials for t ...... andidates: a workshop summary.
@en
Intermediate-size trials for t ...... andidates: a workshop summary.
@nl
type
label
Intermediate-size trials for t ...... andidates: a workshop summary.
@en
Intermediate-size trials for t ...... andidates: a workshop summary.
@nl
prefLabel
Intermediate-size trials for t ...... andidates: a workshop summary.
@en
Intermediate-size trials for t ...... andidates: a workshop summary.
@nl
P2093
P1476
Intermediate-size trials for t ...... andidates: a workshop summary.
@en
P2093
P304
P356
10.1097/00042560-199711010-00009
P407
P577
1997-11-01T00:00:00Z